Lineage Cell Therapeutics (LCTX) Enterprise Value (2010 - 2026)

Lineage Cell Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$63.9 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 29.67% year-over-year to -$63.9 million in Q1 2026; TTM through Mar 2026 was -$63.9 million, a 29.67% decrease from a year earlier, with the FY2025 full-year figure at -$62.2 million, down 39.99% from the prior year.
• Enterprise Value fell to -$63.9 million in Q1 2026 per LCTX's latest filing, from -$62.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$31.4 million in Q4 2023 and bottomed at -$81.3 million in Q1 2022.
• The 5-year median for Enterprise Value is -$47.3 million (2023), against an average of -$51.0 million.
• Across the five-year window, Enterprise Value jumped 47.06% in 2023 and plunged 41.5% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$59.3 million in 2022, then soared by 47.06% to -$31.4 million in 2023, then plunged by 41.5% to -$44.4 million in 2024, then sank by 39.99% to -$62.2 million in 2025, then dropped by 2.8% to -$63.9 million in 2026.
• Per Business Quant, the three latest LCTX Enterprise Value figures stand at -$63.9 million (Q1 2026), -$62.2 million (Q4 2025), and -$33.5 million (Q3 2025).